Feedback
Exome Sequencing, Trio
2006332
Ordering Recommendation

Preferred test to determine etiology of a patient’s symptoms if Mendelian genetic condition is suspected. Parental specimens are required to identify de novo variants and interpret patient results; order Exome Sequencing, Familial Control, Tracking (2006340). 

Mnemonic
EXOME SEQ
Methodology
Massively Parallel Sequencing
Performed
Varies
Reported
4-8 weeks
New York DOH Approval Status
Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
 
Collect
Lavender (EDTA) or yellow (ACD Solution A or B). Peripheral blood required. Contact ARUP's genetic counselor at (800) 242-2787 ext. 2141 if there are questions prior to test submission.
AND Maternal Specimen: Lavender (EDTA) or yellow (ACD Solution A or B). Peripheral blood required.
AND Paternal Specimen:  Lavender (EDTA) or yellow (ACD Solution A or B). Peripheral blood required. 
Specimen Preparation
Patient Specimen: Transport 3 mL whole blood. (Min: 1 mL)
AND Maternal Specimen: Transport 3 mL whole blood. (Min: 1 mL)
AND Paternal Specimen: Transport 3 mL whole blood. (Min: 1 mL) 
Storage/Transport Temperature
Refrigerated. 
Unacceptable Conditions
 
Remarks
 
Stability
Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable 
Reference Interval
By report.
Interpretive Data
Refer to report.

Compliance Statement C: For human genetic inheritable conditions and mutations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

Note
For each parental or family member's specimen, please indicate on the test requisition form that the sample is a control and reference the patient's name. Control samples submitted without a separate signed exome sequencing consent form will not receive a clinical report of their ACMG secondary findings or other actionable secondary variants.
Hotline History
View Hotline History
Components
Component Test Code*Component Chart NameLOINC
2006333Exome Specimen
2006334Exome Sequencing Interpretation
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • Familial Next-Gen testing
  • Symptom guided exome sequencing
  • Targeted exome capture
  • Whole-exome capture